MOORE
THOMPSON
INFLAMMATORY NEUROPATHIES UK
(fomierly Gullllan-Barre & Associated Inflammatory Neuropathles (GAIN)
CHARITY COMMISSION REGISTERED NO: 1154843 & SC039900
STATEMENT OF ACCOUNTS
for the year ended
31st March 2026

INFLAMMATORY NEUROPATHIES UK
Contents Page
for the year ended 31st March 2026
INDEX
Legal and Administfalr¥e InforMa￿n
Truslee5' Annual Rep)rt
Independent Examirnf s Repjrt
Statement of Financial Actmties
Statement of Financial PosI￿n
10
Notes lo the Accwnts
11-22

INFLAMMATORY NEUROPATHIES UK
Legal and Adminlstrative Information
for the year ended 31st March 2026
Trusteos
Carol Hooper- Chair
Sean Austin - Treasurer
Jenny Willison (resigned 4 October 20251
Lee Raynor Iresigned 4 October 20251
Jatinder Paul
James Wilson
Stephanie Parker
Lora Barelay
Derren Sanders lappoinled 16 October 20251
Prn81dtnt Emerltus
Glennys Sanders MBE
Patron•
Air Marshal Sir lan Maclayden KCVO CB OBE FRASS RAF Rld
Professor Richard Hughes MD FRCP Fmedsci
Chlèf ExoGUtlve Offlcer
Rich Collin8
Reglstered Offlco
3 Mill House
Carre Street
Sleaford
Lincolnshire
NG34 7TW
Indepèndent Examlner
H J Bri9ht BA, FCA. CTA
M¢)ore Thompson Limrted
Bank House
Broad Street
Spalding
Lincolnshire
PE11 1TB
Bankers
CAF Bank
25 King's Hill Avenue
West Malling
ME194JQ
Page 1

INFLAMMATORY NEUROPATHIES UK
Trustees. Annual Report
for the year ended 31st March 2026
The Injslees of Infflammalory Neuropath*s UK present th￿[ annual report for the year ended 31 Mareh 2026
under the charit￿S Act 2011. The report has been prepared in accordance wrth Inflammalory Neuropathies UK'S
governing dttumenl and the Statement of ReC￿nrnended Practti (SORP FRS 1021 Financial Reporting
Standard appI￿ab￿ in the UK and the Republ￿ of Ireland.
Our legal slalus and governance structure are explained in Ihe'struclure, govemance and management, section
of this report.
The Charity operated under the name GuilLgin-Barré and Assctiated Inftammalory Neuropath*s (GAINI until 1st
May 2025, when the name changed lo Infiammatory Neuropathie5 UK.
ObJ•¢llv•8 and Actlvh
iv
Inflammatory Neurcpath*s UK is the onty UK chaity ￿ttl¢h ffj ccffnp￿tsty ￿ed￿ated lo supporting people
impxted by GUil￿1n-Barlè SyndrcAne IGBSI, CIDP, MMN, and other Infiammatory Neuropathies.
We offer support lincluding eMOt￿nal supForti. personal grants, local groups, online fowm$, and much more.
We provNJe support ab)ng$￿e a community of peop￿ wrth lived &xpenence, supporting people lo help each
other. We false furKls for reseafch and even carry out some soekql research oursefves. We work right across the
UK, also providing support lo Feople in the Republ￿ of Ireland rf they ask for rt.
We are here for people ¥￿ether they have one of these condth"on$ themselves, are Suppth'ng a fri￿￿ or a
family member. or afe a medKal professional.
We arg Infflammatory Neuropath￿ UK. and wg are IN this loJetlw.
Thè Iruslees eonfim) thal they have referred lo the inf0mat￿n contained in thè Chafty Crynmi$$ion's general
guidanee on publ￿ benefrt then revwng Ihe Charrty's aims and objectNes, and In planning actiwties and
strategy for the year ahead. The aclTvil*s that we cary out to further tyjr Charrtab￿ purpose5 are for the public
benefrt.
Our objectives, as set out in our Constr(uiw. are lo rel*ve the need$ of people impacted by Inflammalory
Neuropathies. Ihwr families, and cafers in particular bul nol exclusivety by.
8. The provision of infomiatw. support. rw)n-medtsl advu. aThJ other assistance".
b. The prcrfnotion of re50arch into the causes. prew11￿, and treatment of Infiammatory Neuropathies., and
. Advancino the awareness of the publ￿ and of the med￿1 profess￿ft$ conceming InfI￿rnatory Neuropathies,
their cau8e8. impacts, prewnlion, 8nd treatment.
Achievemonts •nd wrfomi•n¢•
202512026 was another excel￿nI yaar for Inflammatory Neuro￿h￿ UK. We have continued to gT¢)w and
develop. and to reach and support more people. This woukln'l have been ￿sIble wthoul our incredible staff,
team. our amazing volunleefs, arKI our dedicated Board of Twsteas.
rtin
im
drtp)ns.
Peopbe are a￿y$ at the centre of evtyhing that Inflammatory Neufopalhes UK does, and that has been no
sjifferent in 2025r26. Oui Inllammatory Neuropathies Communty ￿ad5 eve￿hing we do, and we have Gonlinued
to engage with and listen lo peop￿ on a regular basis. to ensure our servw and our support are what people
want and need.
Foll¢Mng on from the sMJnrfKanl slrKles foTrvard we made kgsl year. we continue lo deveh)p our core offer, and
add now opportun1th￿ to the rnenu of 8ervr*s we provide and make available to our Gommunity. We hav¢
lurther ensured that suppcKt is our primary focus. and are c(x)linuousty improvin9 how we respond lo enquiries
and offer support Our person-cenlred approach, rather than a service-led model continues to evofve. and we
have add￿ In and emotional support Serv￿ in 2025. as well as further devek)ping inhouse provision, targeting
support lo indiwdual needs on a bespoke basis. and rev￿￿n9 arKI broadening our key Se￿iceS SLbch as our
Online and Lc￿1 Get Togethers. The key aim of thts eontinue(l improvement and devek)pment has been lo
reach more Feople and to improve the SUPF#Jt they receNe fr(Mn us.
Page 2

INFLAMMATORY NEUROPATHIES UK
Trustees, Annual Report
for the year ended 31st March 2026
hi9¥gments and perfomiancè continued
As a result of these changes and our different approa¢he$, we have once again been able to 8UPPQrt an
increased number of people. In 2025126 we directly supported 937 people, an increase of 57% from the previous
year We also monitor the number of activities that we undertake In support of people. In 25126 this was 5,349,
an increase of 630h.
Of the 937 people supported, 48 received peer support from one of our incredible volunteers, and 25 pgople
received a Personal Grant, an increase of 670A, with a total spend of £24.941. In addition to Ihesg figures, we
received the Initial report from Rareminds with regard to our new Emotional Support Service up lo Ihe end of
2025. This saw an inrtial 9 pèople supported, through 62 Sessions of support, with 1000A highlighting positive
outcomes.
We were al80 ab￿ lo increase the number of peopLq supported through OUT onlin8 groups. wlh 138 people
attending throughout the year. These groups continue lo be popular with regular attendees, pgople newly
diagnosed, and those who want ad hoc connections and support when they need it. We added a new MMN
group in February, providing an additional ¢ohort ol peopL* with this support.
As athys, there was a significant demand for in pefson support, and our L¢xal Gel Tc>Jethers We￿ there to
deliver it. We have been working hard wilh our volunteers and our communrty lo recruit fa¢ililalors and to grow
the number of groups provided In 202S126 we launched a new Essex Gel Together, which has joined
Lan¢ashire and Cumbria, and Yofkshire as regular groups. We held one off L¢cal Get Togelhers in Bimiingham
and Edinburgh, bul these did not continue past their Initial meeting. As a re$ull. we did not hrt our grovAh target,
bul have successfulty recruited more volunteers lo this role. and are on target to grow tho number of group$ in
26127.
During tho year. our membership eonlinued lo grow. alkil al a 188ser rale than last year. In 25r26 ￿ ended th•
year with 1,826 members, an increase of around 2.3%
One of our biggest strategic aims is lo increase our reach and engagement. By reaching more people, we can
support more people. We have strived lo do this In a number ol ways. Our social media presenee ha¥ grown
signifieanlly wrth 15% more followers across all channels, a 310A increase in enga9emenl. and an average of
80.000 impressions on social media per month. Thi5 has been a great 8UCCèSS.
Our website has al80 s¢on significant gr0￿h, particularty following the launch of the new website under the
Inflammatory Neuropathies UK branding. The website saw 70,091 user last year, and an increase of around
57.50h.
Our annual survey again demonstrated that the monthly newsletter was important lo people. We sent out 12
newsletters in 25126 to a steadily gr¢)wing number of Subscribers. On average this was ofound 1,950 people
each month, and a total of over 23,000 people over the year. Newsletter emails are opened on average by
26.5% of people. meaning around 6.100 people were reached and inleraeted wrth ono of our new51etter5 in
25126.
We continue lo improve our monitoring and reporting on impaci. ouleomès, and outputs. While there Is still some
way lo go, we are now reporting monthly on a wider sel of impael measures, whrh allow u8 to better understand
what we delivor. and how we can make improvements. We have further developed and improved our Imp&t
Report, and continue lo undertake an annual survey of our community, lo best understand what people want and
need, as well as what they expect from the Charrty. This and the metric$ from our performance are used to
improv6 what we do on a constant basis.
Trials and research
As a charity. we always want lo support research. and in 2025126. we were able to fund Universty of Oxford
£25,000 lo support a PhD student's research into antibody research.
This year we also supported 2 clinieal liials, and around 5 rgsearch inrtiatives. We delwered a pl￿? of reSea￿h
in collaboration with other organi5ations IhBt lod to two poster presentations with Innammatory Neuropath￿ UK
branding. We a150 responded to over 10 natk)nal and international consultations.
We worked with over 20 organisalions on collaboratwe approaches, campaigns, and development opportunrties.
Page 3

INFLAMMATORY NEUROPATHIES UK
Trustees. Annual Report
for the year ended 31st March 2026
Achievements and p•rfornian¢• ¢ontinu8d
Every year. wo undertake an annual survey with c￿r Community, as part of an active listening and engagement
prtsJram. We undert￿k our survey In early 2026. in o¥der to better understand how we were performing, as well
as finding out what people's expectat￿n$ were of us.
Responses in 2026 were up on 2025. and we I￿10 ab￿ to gathèr some excellent infofmatKJn lo hèlp guide our
work In the year ahead.
Key takeaways were
. People tho*Jghl we supwrted people V*Èll. and commun￿led effectNety
- Pecple thought we could improve our adve￿CY work. •wareness raising. and résearch
- Pecple wanted better ￿5S to emol*)nal and mental health Sup
- Pecplo wanl¢d more epp)rtunrties to Connect wrth othe(s
Over 25r26 we were abk to continue buikling on our awareness raisir@. marketing, and engagement. This locus
has allowed us lo $￿n￿1¢an1ty increase our reach and engagement. %wth sockil media and the websrte being the
focus ol this adNty. This was drwen from May ty our rebranding exefcise. wh￿h &iw US fename and rgbrand
the or9anisatNJn The feedback ol thts exercise has been overythelmingly positNe. ￿th the new name being well
rgceived, the new1090 and branding being much loved. and comments around a more profossKJnal and
inclusive brand being much appreciated.
Partnership and collaboration remain front and Cent￿ lor lh* Charrty, wrth continued work wrth colleagues
worthide, and xross the sector in the UK. These link5 have helped wrth our Influence and a(Ivocacy work,
Supported our reach and our imp%t. and helped us lo better establish oursefves wrth both a national and glcl)al
voice.
We continue to build batter links wrth polw makers and decisv)n mokeis within thè various levels of UK
Govemmenl, and beyond This has ￿ us lo meelings wrthin the Houses of Padiament and Lords. as well as in
Holyrc¢)d. We continue to build <Jn these links both IKffle and 8bro&l. In order to amplfy the voices of our
Communty.
As wrth all charrt￿$. our fvndraiwng is prone to fluctuatwis link•J lo our varicmjs income str6am$. Thi8 year, our
overall inccme 16 up $vJnrf￿anIty. ThL8 ts largety due to r￿1VIng 8 number of large legacies in the year
However. rt should be r￿ed that our overall donatKJn5 a￿ also up on the comparative fvJures of last year,
showng gcoj perfomiance and defying IrerKJs seen else%there across the sector
As noled bebw. we are V•¥)rking on places to ensure that all of these fttrnds are effectivety and eff￿lentlY utilisod
in accordance wrth our Chantab￿ aims. and the benefrt of the c¢¥nmunty ￿ Serve.
for the comin
Wrth our organisational Strategy and financial strategy in pL%e. we have been ab￿ to frKu6 on both delivery and
future devel¢Jpment.
In 202sr26 we wefg abl8 to..
- Improve Direct Support for Pecple
- Grow Ouf Core Offef
Introduce the EmolK)nal Support Serv
- Improve Reach and Eng8oemenl
- Iwnprove InfomiatMJn
The focus of our strategy over 2026r27 will be."
Intr0dL￿tiOn of Lctal Champv)n8
- Further devebpmenl of the L(tsl Get Ttwhers Nei*D
Facilrtation of Swal Research
- Improved Data ColleCt￿n arKI Us>Je
- Improved Advocacy of our Communty
P4e4

INFLAMMATORY NEUROPATHIES UK
Trustees. Annual Report
for the year ended 31st March 2026
Financial rèview
a. Goin
Concem
After making appropriate enquiries. the Iruslees have a reasonab￿ expectation that the Charty ha5 adequate
resources to continue in operational existence for the foreseeable future. For this rea50n, they continue lo adopt
the going concern basis in preparing the financial stalemenls. Further details regarding the adoption of the going
con¢ern basis can be found in the Accounting Polieie5.
b. Our finances for our
r 2025126
Our consolidated financial 518lemenls for the year are shown on pages 9 10 22. A summary of the financial
results lor the year is sel out below.
In
min
re
Toial income for the year was £510,498 which showed a increa¥e of £314,386. Thi8 was due to a increase in
legacy donations.
This year has seen expenditure in¢rease from £203.288 10 £286,760 . This equates to an inerea$• of around
41.1Q/o.
If we look al income as a whole. we can see that our strategy lo diversify our income has begun lo take effect.
with grants and research income added in the year. Our position with regard lo donations and lundrai¥ing is faidy
siable, with performancè actually increasing in some key areas. This is against the trends seen with the majonty
of charities, and we aro delighted that the generosity of the public has bèen so posrtive in 25126.
Even with our financi81 strategy in place. the unprediclabilily of income means that il remains difficult lo predlcl
income and lo plan accordingly. However, as wrth last year, careful budgèt planning, management and
monitoring by our Financial Sub-committe8 has delivered better financial performance than èxpected.
Our policy is lo invest lunds In the ongoing expansion of our work, bul lo relain sufficient levels of available
reseNes lo enable us to continue our core slralegi¢ activities in the event of a signrficanl downturn in our
ineome. This considers risks associated with our income streams. our ongoing investment in delivering our
strategies, the varying need$ of our members, longer term cash flow projections, and other relevant business
We have identified sufficient levels of available reserves as being a minimum of 6 months of our planned
expenditure. We reeognise Ihat there may be circumstances where reserve levels fall below this largel range.
H¢)wever. if this was the case, there would be a clear action plan lo restore them.
Our investment policy for these reserves is reviewed by the Board on an annual basi5, Our object￿e Is lo seek lo
produce the best financial return wthin an acceptable level of nsk for the bulk of the assets, referred lo as the
Yinancial investments,. Tho Investment portfolio is invested to direclty further the Charity's aims. The
performance of our investments is kept under review.
We keep our funds with UK-based institutions with a strong credit rating. and we keep our policy under review in
the light of changes lo the financial climate The Board of Trustees has reviewed the Inflammatory Neuropathies
UK financial position and believes the￿ are sufficient resources lo manage any operational or financial risks.
As of 31 March 2026, our total funds to be Carried over were £1,243,06012025126'. £992,579). Of this amount.
£1,278,90312025126.. £1,002.5211 represent5 the assets of the Charity, including the land and buiklin9 that wo
own. Our policy is that we should have a minimum of 6 months, operating costs In reserve. This equales to
approximately £169,000. We calculate free reserves lotaling £918,864 as of Mafch 202612025126.. £709,059).
Structure, governanc• and management
The Charity was founded in 1985 and rebranded as a CIO in 2014. The Charty 15 a Charitable Incorporated
Organisation and is regulated by the Charity Commission in England and Wales- no 1154843 and the offi￿ of
the Scottish Regulator- no SC039900.
Our constiiution was updated following our name change in May 2025, and again wrth some minor change8 to
update wording in October 2025.
Page 5

INFLAMMATORY NEUROPATHIES UK
Trustees, Annual Report
for the year ended 31st March 2026
Structure. govemance and management contlnued
Tr
Our governing body, the Board of Trustees Ilhe Board), is responsible for the overall governance and work of the
Our Iruslees are volunte8rs and do not receive any remuneration for their services, bul may Claim reasonable
expenses incurred through attending meetings or other duties. The Board meels monlhty and is responsible for
directing the affairs of the Charity, and ensuring that il is solvent, well run and delivers the charrtable outcomes
for the benefrt of people impacted by GBS, CIDP, and related condrtions. Trustees who served during the year
are listed on page 1.
Trustees can be recruited from w((hin the membership or from Olrtside The Trustees are elected by the
membership at the Annual Genoral Meeting. The full terms for Trustees can be found in our Constrtution.
During the year Jenny Willison and Lee Raynor retired a$ Trustees having seNed their full terms. We woukl like
lo thank Jenny and Lee lor their work with and support of the charity over their tenures.
inin
ru
Potential Iruslees attend an interview lo assess their suilabilily for the role Al this inlgrv1ew they are also told
about the r8sponsibililies of Trustees,. the Conslilulion and other documontalion., the linancial silualion., and
existing strategy. Following interview, successful applicants meet the whole Board al the next avai18ble Board
moeling as an observer.11 the Board is Satisfied and the applicant wishe$ to proceed, they will bg invited to loin
and are co-opted until the next AGM at which lime they may sland for election.
The Board deleg8les operalional planning and day-lcpday management of the Charity to the Chief Executive,
supported by the Charity's 8tsff. Th￿ authority Is delegated within approved limits. Staffing lfrvels are foul full-
time staff.
We have a comprehensive nsk regi81er which considers plans and stralegias lor rniligaling risk. The register is
reviewed throughout the year by the Chief Executive who updates the Board on tho slalus of the key risks and
issues, as well as any mrtigalions. as part of the regular reporting lo each Board meeting.
Tru8tee8' responslbllltles statement
The Trustees are responsible for proparing the Trustees, Report and the financial slalemenls in accordance wrth
applieable law and Unrted Kingd¢)m Accounting Stsndards (United Kingdom Generally Accepted Accounting
Practice).
The law appI￿able to ¢harilies in Englandlwales & Scotland reqLti￿S the Tw$loes lo prepare financial
slalements for each financial year which give a true and lair view of the slate of affairs of the Charity and of the
incoming resources and appliealion of resources of the Charity for that period. In prepaiing these financial
Statements, the Trustees are required lo..
$8lècl suitable accounting policigs and then apply them consislenlty.,
observe the methods and principles In the Charrties SORP IFRS 102}",
make the judgements and accounting eslimales Ihal are reasonable and prudent.,
prepare the financial statements on the going concern basis unkss (( is inappropriate to presume that
the Charity will continue in operation.
The Ifuslees are responsible for keeping adequate accounting records that are sufficient lo show and explain the
Charitys tranaaGtions an(J di8clo8e with rea?onable aGcuracy at any time the financial po$ition ol the Charity an
enable them to ensure that the financial statements comply with the Charrties Act 2011, the Charity (Accounts
and Reports) Regulations 2008, the Charities and Trustee Investment (Scollandl Act 2005. the Charrties
Accounts (Scollandl Re9ulalions 20(￿ las amended) and the provisions of the Memorandum of Association.
They are 81s0 ￿SPOnSible tor safeguardin9 the assets of the Chanty and hence foi taking raasonable steps for
the prevention and detection of fraud and other irregularities.
This report was approved by the Trustees, on 3rd October 2026 an¢J is signed on their behalf by..
Carol Hooper, Chair
Page 6

Independent Examinerfs Report to the Trustses of
INFLAMMATORY NEUROPATHIES UK
for the year ended 31st March 2026
l ￿port lo the charty Iruytees on my examination of the accounts of the charity for the year ended
31 March 2026 which are sel out on pages 9 to 22.
R•sponsibilltles and bas5$ of roport
As the Trustees of the Charity you are responsible for the preparation of the accounts in 8ccordan¢e
with the requirements of the Charf(ies and Trustee Investment Iseollandl Act 2005 Ilhe 2005 Aet'l, the
Charities Accounts (Scollandl Regulations 2006 las amended) I'lhe 20C6 Accounts Regulalions'l and
the Charities Act 20111'lhe 2011 Ad'l. You are satisfied that your charrty is not required by charrty l&Y to
be audited and h8ve chosen instead lo have 8n independent examination.
I report in respect of my examination ol the Charitys accounts carried out under section 4411 Ilcl of the
2005 Act and seelion 145 01 the 2011 Act. In carrw'ng out my examination I have followed Ihe
requirements of Regulation 11 of the 2006 Accounts Regulations and all applicable Directions given by
the Charty Commission under section 145ISllbl of tho 2011 Aci.
Indopendent oxamln•rf¥ ¥tatem8nt
Since th8 Charity has prepared ils aeeounls on an accruals bas¢s and is regislor¢d in Scotland your
examiner musl be a member of a body listed in Regulation 11121 of the 2006 Accounts Regulations. I
can confirm that l am qualrfied lo undertake the examination because l am a regislereil member of
Institute of Chartered Accounlanls in England and Wales. which is one of the listèd bodies.
Your attention is drawn to the fact that Ihg Charity has prepared the accounts in accordance vAlh
Accounting and Reportin9 by Charrties.. Statement of Recommended Practicè applicable to charil*s
preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and
Republic of Ireland IFRS 1021 in preference to the Accounting and Rèporting by Charrties.. Statement of
Recommended Practice is$Ltgd on 1 April 2005 which is referred to in the extant regulations bul has
been withdrawn.
l understand that this h85 been done in order for the accounts lo provide a true and fair vow in
accordance with the Generally Accèpted Accounting Practice effeetive for reporting periods beginning
on or after 1 January 2015.
I have ¢ompleled my examination. l ¢onfim that no material matters have come lo my attent￿n in
conneelion wf(h the examination giving me cause to beI￿ve that in any material respect..
1. accounting records were not kept in respect of the Charity as required by Section 4411llal of the
2005 Act, Regulation 4 of the 2006 Accounts Regulations, and section 130 of the 2011 Act.. or
2. the accounts do not accord with those iecord8', Of
3. the accounts do not comply wlh the accounting requiremonls of Regulation 8 of thè 20C6 Accounts
Regulations and the applicable requirements Concerning the forrn and conlenl of accounts sel out in
the Charities (Accounts and Reports1 Regulations 2008 other Ihan any requirement that the accounts
give a 'lrue and fair, view which is not a matter considered as part of an inde￿ndent examination.
I have no concerns and h8ve come across no other matters in connection wrth the 8xaminalion to which
attention Should be drawn In this feport in order to enable a proper understanding of the aecounls lo be
ached.
Page 7

Independent Examinerfs Report to the Trustees of
INFLAMMATORY NEUROPATHIES UK
for the year ended 31st March 2026
This rewrt is made SOW to Chartys Trustees, as a trK*Jy, in xcordance with Part 4 of the Charrties
(Accounts and Reports) Regulations 2(￿ and ReguL9t￿n 11 of the ChantEs Accounts {Sc()tlandl
Regulations 2006. My wod( has been undertaken so thal I might stale to the Chartys Trustees those
matters l am required to slate to them In an Independent Examine¢s Report and lor no other purpose.
To the fullest extent pemiitted by law. I do not accepl or assume responsibility lo anY￿e other than the
Charty and the Chantys Trustees as a bc4*, for my or for this report.
Heather Bnghl BA IHonsl, FCA. CTA
Moore Thompson Limfted
Chartered Accountants
Spalding
08te'.
Page 8

INFLAMMATORY NEUROPATHIES UK
Statement of Financial Activities (Income and Exponditurn Aeeount
for tho yoar èndèd 31st March 2026
Notes
2026
Unro$tricted
funds
2025
Totsl
Total
Incomo from..
Donations and legacies
Fundraising
Other trading activities
Investments
490,369
1,333
5,004
13,792
490,369
1.333
5,004
13,792
174,840
3.843
3.979
13.450
Total IncomSng rosourc•$
510,498
510,498
196,112
Expgndlluro on:
Raising funds
Charitable activities
4.253
282.507
4,253
282.507
6,266
196,962
Total •xpend•d reBourc••
286,760
286.760
203,228
Net Incom• boforo g•ln•lllos•os on Invè•tm•ntsl
223,738
223,738
17,116
Nel gains I Ilossesl on inve5tmenl$
Nel g8ins I Ilossesl on inve8lmenl propertie$
5.093
21,650
5,093
21,650
4,906
Not mo¥om•nt In fund•
250,481
250.481
12,2101
Reconclllatlon of fund•:
Total funds brought forward
14
992.579
992,579
994,789
Totsl funds carrfed fo￿ard
11
1,243.080
1,243,060
992,579
All income and expendilure derive from continuing a¢livili&s.
The slalemenl of financial ath'vlb'es Includes all gains and losses recognised during the year.
The notes on pag9s I 110 22 fomi part of Ihese lin8nci81 statements
Page 9

INFLAMMATORY NEUROPATHIES UK
Statement of Financial Positlon
at 31st Ma￿h 2026
2026
2025
Totsl
Total
Flxèd ass•ts
Tangible assets
Investment propety
Inve$tment$
24,196
300,000
121,672
283.520
116.579
445.868
400,099
Current assets
Debtors and prepayments
Cash at bank and in hand
7.291
825,744
21.983
580.439
833.035
602.422
Cr•dltorn:
Amounts falling due wfjthin one
135,843
{9,942}
N•t ¢urr•nt a•s•t•
797,192
592,480
Totsl al￿14 l••• curr•nt Ilablllti
1,243,060
992,579
N•t A•••ts
1.243.060
992.579
Ch•rSty Fund•
Unre$lricted
11
1,243.060
992,579
1.243.060
992,579
These finanaal stateff*nl$ vwe approved by the Trustees and are signed on their bettalf by"
Carol Hooper
Chair
Date." 3rd O￿ober 2026
P8ges 1110 22 fonn part of these f￿anCIal statements
Page 10

INFLAMMATORY NEUROPATHIES UK
Notes to the Financial SLit•mènts
for the year ended 31st March 2026
1. Genoral Infom)ation
Inflammatory Neuropathies UK Is a Charitable Incorporated Organisalion Regislefed in England and
Wales. The pnncipal office address is 3 Mill House, Carre Street, Sleaford. Lincolnshire. NG34 Trw.
Accounting Policies
2.1 8asis of preparation of financial statomonts
The financial slalemenls have been prepared in accordance wi(h the Charrties SORP IFRS 1021-
Accounting and Reporting by Charities." Slalemenl of Recommended Pracliee applicable lo charrties
preparing their a￿Ount$ in accordance wilh the Financial Reporting Standard applicable in the UK and
Republic of Irojand IFRS 1021 (effective 1 January 20151, the Financial Reporting Standard appl+¢able in
the UK and Republic of Ireland IFRS 1021 and the Charities A¢t 2011, the Charities and Trustee
Investment IS¢ollandl Act 2005 and the Charities Accounts Iscollandl Regulations 2006 las amended).
The financial ststemenls have been prepa￿￿ lo give a 'lrue and fair, view and have departed from the
Charities (Aceounls and Reports) Regulations 2008 only lo the extent required lo provide a 'lrue and fairf
view. This departure has involved following the Chanties SORP IFRS 1021 published on 16 July 2014
rather than the Accounting and Reporting by Charities.. Slalement of Recommended Practice affèctive
from 1 April 2005 which has sin¢8 been ￿￿thdraWn.
Thè financ￿1 slalements have been prepared under the historical cost convention wrth rtem recogni$ed at
ost or transaction value unless otherwise slated in the re￿vant notes to these accounts. Tho financial
ststemenls are prepared in sterling, which is the functional currency ol the Charrty. Monetary amounts in
these financial ststemenls ale rounded lo the nearest £.
Inflammatory Neuropathies UK meets the definition of a public benefit enlily under FRS 102. Assets and
liabilrties are initially r¢¢ognised al hislori¢al ¢osl or transaction value unless othe￿iSe slated in the
relèvant accounting policy.
2.2 Golng Con¢em
After making appropriate enquiries. the Trust￿ have a reasonabl8 expectation that the Charity has
adequale resources lo continue in operational existence for thè foreseeable future. The Trustees deemed
that the Charity can meet ils commilmenls and liabilities and can continue for the foreseeable future.
Accordingly, they ¢onlinue lo adopt the going concern basis in prèparing the fin8nci81 stalemenl$.
2.3 Incom&
All income is reco9ni$gd once the Charity has gnlillement lo the income, f( is probablè that the incom& wll
be received and the amount ol incomg receivable can be measured reliably.
The recognrtion of income from legacies is dependent on establishing enlillemenl, the probabilty of
receipt and the ability to g$1imale with suffieienl accuracy the amount receivable. Evidence of enlrtlement
lo a legacy exists when the Charrty has sufficient evidence that a gift has been left lo them (through
knO¥￿edge of the exislenco of a valid will and the death of the benefaclorl and the executor is salisfiad
that the property in question will not be required lo satisfy claims in the estste. Receipt of a legacy musl be
recognised when rt Is probable that it will be received and the fair value of the amount receivablè, which
will generally be the expeeted cash amount to be distributed lo the Charity. can be reliably measured.
Income from trading 8Ctivrties and fundraising is received in exchange for Supplying goods and services in
order lo r8ise funds and is recc>Jnised when enlrtlemenl has occurr&J.
Income tax recoverable in relalion lo donations received under Gift Aid or deeds of covenant is
recognised al the lime of the donation.
Income tsx recoverable in relalKJn to investment income is recognised al the lime the investment
InGome 15 receivable.
Inleresl on funds held on deposit is included when receivable and the amount can be measured reliably by
the Charity.. this is nomially upon notrfication of the interest paid Of payable by the institution with whom
the funds are deposited.
Page11

INFLAMMATORY NEUROPATHIES UK
Notes to the Financial Statements (continued)
for the year ended 31st March 2026
Accounting policies Icontinuedl
2.4 Expenditure
Expendrture is rec(*Jntsed once tlwe is a legal or constructi4E Obl*3at￿Tr lo transfer economic benefit to a
third paty. it is probable that a transfer of economic benefrts will be required in Sett￿ment and the amount
of the 0b1NJ8t￿n can be measured rdiabty. Expendrture is classrf￿d by actsvty. The costs of each actNity
are made up of the total of direct costs and shared costs. i￿luding support costs Invo￿ed in undertaking
each aclNity. Direct costs artr￿lrtab1e to a single actNrty are al(tsled directty to that activity. Shared costs
which contribute lo MO￿ than one actmty and suppcKt costs which are not attributable to a single aclmty
are apportioned bth*n those activrties on a basis consistent wrth the use of resources. Central staff
costs are allo¢oted on the basts of lime spent. and depreciatK)n charges althaled on the pO￿.0n of the
asset's use.
Expenditufe on raising funds includes all expenditu￿ incurreil by the Charrty lo raise funds for rts
charrtable purposes and includes costs of all fundraising actMtEs events and non<hantable trading.
Expenditure on Charrtab￿ actNf(ies Is incurred on dÈrectty undertaking the activrties whrh further the
Charty5 objectives. as well as any associated support costs.
Grants payable are charged in the year when the offer is made except in those c2ses where the offer is
conditional, such grants being recognised as expendrture when the condf(ions attachirg are fU￿lISed
Grants offered subject lo condrtions haNE not been met at the year eThJ are noted as a commitment,
but not accrued as expendrture.
All eXpendrtu￿ ts inclusive of Irrecoverab￿ VAT.
2.5 Tangible fixed assets and depre¢lation
Tangible fixed assets are initialty reccgnised at CC6t. After re¢ognitK)n. under the c05t model. tsngible
fixed assets are measured at cost less accumuLated deprecwtk)n and any accumuLaled Imp81mienl
losses. All costs incurred to bring a tangib￿ fixed assét into rts Intended hfvDrf(ing widitKsn should be
induded in the measurement of cost.
DeP￿￿tIOn 15 eharged so as to alkxate Ihe c05t of tsngible fixed assets less their resKlual value over
their estimated useful lives. using the strawjht-line methc*J.
Depr￿latIOn is prowded on the following bases".
Freehokl propety (excluding landl
Property fixtures and ffttings
Office equipment
CompLrter equipment
- stra￿h1 line over 50 years
stra￿bI line over 10 years
25°A slraight line
25¥0 slrwght line
2.6 Investments
Fixed asset investments are a form of firbancral Inst￿Ment and are inrtplty recognised at th￿r transact
st and subsequentty measured at fair value at the BaLonce Sheet dale, Un￿$$ the value cannol be
measured relkqbly in whKh case rt is measured at cost W impaiment. Investment gains and losses,
whether realised or Un￿all$ed. are combined and presented as 'Gainsl{Lossesl on investments, in the
SL*ement of Financ￿1 Aetmties.
2.7 Investments Propertlgs
Investment propefrtes are measured at fair value at each reKK)rting date with changes In fair value
recognised in "net gains I Ilossesl on investment properties- in Ihe Statement of Financ￿1 Aetivf(ie$.
12

INFLAMMATORY NEUROPATHIES UK
Notes to the Financial Statements (continuèd)
for the year ended 31st March 2026
2.8 Debtors
Trade and other debtors are rewgnised at the settlement amount after any trade discount offered.
Prepayments are valued al the amount prepaid net of any trade discounts due.
2.9 Cash at bank and In hand
Cash al bank and in hand includes cash and $hort-term highly I￿Uld investments wfth a short maturity of
three months or1è5s from the date of acquisition or opening of the deposit or similar account.
2.10 Lbabllllles ¥nd provlslons
Liabilities are recognised when there Is an obligation al the Balance Sheet dale as a result of a past event,
il is probable that a transfer of economic benefit will be requiied in settlement, and the amount of the
settlement can be estimated reliably.
Liabilities are recognised al thè amount Ihat the Chafily anlicipales il will pay lo settle the debt or the
amount it has received as advanced payments for thè good8 or sorvices il musl provide.
Provisions are measured al the best estimate of the amounts required lo settle the obligation. Where tho
effect of the lime value of money Is material, the provision 18 based on the present value of Iho$fj
amounts. discounted at the pre-tax discount rale that reflects the risks specific lo the liability. The
unwinding of Ihe discount is recognised in the Slalemenl ol Financial Activities as a financè cost.
2.11 Flnanclal Instrumonts
The Charity only has financial assets and financial liabilities of a kind that qualfy as basic financial
inslrumants. Basic linancial in51rumenls are inrtially recognised al transaction value and subsequent
measuied al their settlgmenl value with the èxception ol bank loans which are subsequently measured at
amortised w&1 using the effectivo interest melh(>a.
2.12 Pen8lons
The Charity operat88 8 defined contribution pengion scheme and the pansion ¢harg• iepresenls the
amounts payable by the Charity lo tha fund In respect ol the year.
2.13 Fund Accountlng
General funds are unreslrieled funds which are available for use at the discretion of the Tru$lee8 in
furtherance of the general objoclives of the Charity and which have not been designated for other
puiposes.
Designated funds comprise unreslricled funds that have been set aside by the Tru$lees for particular
purposes. Thg aim and use of each designated fund is sel out in the notes lo the financial statemonls.
Investment income, gains and losses are allocated lo the appropriate fund.
Analysls of Incom•
2026
026
Unre8trlcted Rostrlctgd Endowmènt
Funds
Funds
Funds
2025
Total
Total
Donatlons and Legacles
Donations
Grants
Legacies
132.9
5,000
352,379
490,369
132,990
5,000
352,379
490,￿9
157.980
16,860
174,840
Fundraising
Fundraising
1,333
1,333
1,333
1,333
3,843
3,843
Other Tradlng A¢tlvltles
Res¢ar¢h
Sales of cards and 9oods
2,WO
2.000
3.004
5.004
3.004
S,004
3,979
Invoslrngnt Income
Interest income
13,792
13.792
13,792
13,792
13,450
13.450
510,498
510.498
196,112
Page 13

INFLAMMATORY NEUROPATHIES UK
Notes to the Financial Statements (continued)
for the year ended 31st March 2026
4. Analysls of Exp•nditurn by activities
2026
2025
A¢ti¥lties
Undertaken
Directly
Grant
Aclivit•es
Support
Costs
Totsl
Total
Research and raising awaoness
36.814
49.941
195.752
282,S07
196.%2
Raislng
Aw•r•n688
16.884
19.930
2026
Total
16.884
19.930
36.814
2025
Total
16.503
Anatysls of Dlrnct costs
Advertising & marketing costs
Project Costs
16.503
Raising
Awarenes•
129,456
3.708
2026
Total
129,456
3,708
2025
Total
99,386
1,453
9.270
13,774
329
12231
Analy818 of support costs
Staff cosls
Staff training and wiferences
Staff ageney costs
Depreciation
Rrfruitmenl
Water rales
Repairs
Miscellaneous
Licenses and Sub￿ript￿)n#
Rent arKI servKe charge
Tebphone and Computer
Print and postage
Insurance
Equipment hire
Travel
Legal and prOfeSs￿n81
Bank charges
Accountancy
Office eosls
c￿anIng and waste di8poso1
Govemance costs . trustées expenses rembursed
117,7111
345
181
8.880
2.208
8,194
3.624
S.257
7,329
2,121
12.402
8,178
13,405
128
3.540
2,622
1,820
65
195.752
117,711
345
181
8.880
2.208
8.194
3,624
5,2S7
7,329
2,121
12,402
8.178
13,405
128
3.540
2.622
1,820
65
195.752
831
4,131
624
3,710
5,445
1.925
11.885
3.186
4,270
187
2.826
2,803
2,109
1,340
Grants to
Grants to
Institutlons Indlvidual
25.OC(I
24.941
25.oc
24.941
2026
Total
49.941
49.941
2025
Total
10,412
10.412
Anatyils of Grants
Grants avrarded
Page 14

INFLAMMATORY NEUROPATHIES UK
Notes to the Financial Statements (continued)
for the year ended 31st March 2026
5. Staff Costs
2026
202S
Wages and salaries
Sc*ial security costs
penS￿n costs
121.355
5,389
2.712
129456
92,S17
4,429
2,440
Average number of empbyees dumg the >tar
Management and administration
2026
2025
The number of emplo￿ ¥vthose empw beneffts (èxcluding empby*r pension e41$1$) exceeded
£60.000 was I12025- 01
Total rgmuneratDn including nat￿nal insurance and penS￿n conlribut*)ns in respect to key managemènt
personnel totalK￿ £71,87012025- £61.142
6. Tru8t•os r•mun•ratlon and •xwnses
During the yoar, no Trustees retsived any remunerat￿1 or benefits I2025- £nill.
During the year ended 31 Mar¢h 2026, tsxpensese totalling £65 were reimbursed or directy lo the
Truslee812025- £1.3401 in respect lo travel costs for meetings.
7. Tanglblfj flx•d aM•ts
Property
Frn•hold Fixtures &
Property Fittings
Office
Computor
Equlpment Equipmont
Total
Cost
Brought frtvd at 1st Apr 2025
Additions
Transfers lo Inve$lment property
Carried at 31st Mar2026
278,350
77,471
2,305
1,315
367,514
1,315
1278,3501
1278.3501
77.471
9,388
3.620
90,479
Depreclatlon
Brought flwd al 1st Apr 2025
Charge for the year
Transfers to investment prcpety
Carried f￿d at 31st Mar 2026
26.079
126.079}
47,723
7,747
83.994
(17.7111
621
55.470
9.388
1,425
66,283
Net book value
At 31 sl Mar 2026
At 31 sl Mar 2025
252 271
283 520
Page 15

INFLAMMATORY NEUROPATHIES UK
Notes to the Financial Statements (continued)
for the year ended 31st March 2026
Fixed asset investments
Investment Unlisted
Property Investments
Cost or valu*ion
Brought flwd al 1st Apr 2025
AddrtKJns
Revaluations
116,579
278,350
21.650
5,093
CarrEd flwd at 31st Mar 2026
300,000
121,672
Net book value
At 31 sl Mar 2026
300 000
121672
At 31st Mar 2025
116579
9. Debtors
2026
Total
2025
Total
Other debtors
Prepayments and accrued income
13
7,278
21,097
7,291
21,983
10. Creditor5: falling due within one year
2026
Total
2025
Total
Trade credi(ors
Other creditors
Other lax8tion and secur
Accruals and deferred income
4,160
705
4.546
26.432
3,047
509
2,950
3.436
35.843
9.942
Page 16

INFLAMMATORY NEUROPATHIES UK
Notes to the Financial Statements (continued)
for the year ended 31st March 2026
11. Funds
2026
At1Apr
2025
Incomlng Outgoing
Resourcos R•sources Trdnsfw5
At 31 Mar
2026
Unrnstrictod funds
Deswna16d lunds
Propety fund
252,271
21,650
26.079 300,000
General fund
740.308
515,591
1286.7601
126,0791
943,(EO
Total fuTrd•
992 579
537 241
286 760
1243 C60
The fvThJs are conslrtuled as folh>4rt:
DeS￿nated funds".-
Pr¢werty fund . thLS fund reflects the market value of the propety hdd by Infiammatory Neuropathies UK.
2026
Unrnslrfcted
Funds
2025
T¢)tal
Total
Tangible f￿ad assets
Fixed asset unlisted investments
Fixed asset inveslmenl property
Current assets
Cfedrtors
24.196
121,672
300.C
833,035
135,8431
24.196
121,672
3(Kl,000
833.035
{35.8431
283.520
116,579
602,422
19,9421
1.243,1%0
1.243.060
992,579
12. Penslon comfflltm•nts
The Charty operates a defined contribLrtK•ns PenS￿n scheme. The assets of the scheme are hekl separalety
from those of the Charrty in an independenlty administered fund. The pension ¢osl charge mpresenls
contributions payable by Ihe Charty to the fund and amounted to £2,71212025- £2.440}. Contribulions
t¢)tslling £705 {2025- £5091 *ere Payab￿ to the fuThJ at the balance sheet date arKI are included in credrtors.
13. R•l•ted party tra￿￿CtiO1v&
Other than disclosed ab)ve ry elSe*he￿ in these fingn¢k41 ststemenls, there were no other transactions wlh
related parties requiring dI￿￿SUre.
14. Lessoe Commbtments under operntlng leas
At 31 sl March 2026 the totsl future mininum ￿ase pawnen15 under non<an¢dlable operating lèases are as
fo11ch￿..
2026
2025
Other operab.ng leases wh￿h exptye..
No later that 1 year
Later than 1 year and not bater than 5 years
Later than 5 years
18,112
21,960
9.472
17.032
P￿e 17

INFLAMMATORY NEUROPATHIES UK
Notes to the Financial Statements (continued)
for the year ended 31st March 2026
15. Lessor Commitments under opgrating leases
Al 31st Ma￿h 2026 the total fLrture minwnum ￿ase Itt￿p1S under non<ancelL4ble OFerating leases are as
follows..
2026
2025
Other operating leases Wh￿ expire..
No kter that 1 year
Later than 1 year arKI Thjt later than 5 ye8lS
Later than 5 years
22.5(K)
43.125
Page 18

Pages 20 10 22 8lso lom7part ollhese finartial statemgrts
8nd s￿W Ihe cwparnlrrfe 2025 fwurgs.
Page 19

INFLAMMATORY NEUROPATHIES UK
Notes to the Financial Statements Icontinued)
for the year ended 31st March 2026
16. Fund comparatlves
Statement of FinancialAdivides
2025
Unrnstslcted
funds
2025
Total
Ineome In)m.'
Donatws andkgacAes
FundTrwr
Other Trading &tMties
Investments
174.840
3,843
3.979
13,450
774,840
3,843
3,979
13,450
Total Incomlng rescwrces
196. 7 12
796, 7 12
Expenditurn on..
Raising Funds
Chaitabk Acbvities
6.266
196,962
6,266
196.962
Total gxpgnded rnsources
203,228
203,228
Net /(loss*s) ¢>n investments
4.906
4.906
Net (expenditurn) /lncome
Net movement In funds
(2,210)
(2.210)
(2,210)
(2,210)
Reconclllatlon of funds."
Total funds fO￿ard
994. 789
994, 789
Total funds canied fonvanl
992 579
992 579
Analysis of income
Unrestricted
Funds
2025
Total
Donations and Legacles
D￿ationS
L8gac*s
157.980
76,860
174, 840
15T,980
16,860
174,840
Fundrai￿ng
FUndth￿lng
3,843
3, 843
3,843
3.843
Other Trading Activities
Sales of ca￿S and gcojs
3.979
3.979
3.979
3.979
Investment Incolive
Investment income
13,4&)
13.450
13.450
13.450
196 112
196 112
Paje 20

INFLAMMATORY NEUROPATHIES UK
Notes to the Financial Ststements (continued)
for the year ended 31st March 2026
16. Fund comparatlves (coneinued)
Analysls of Expendlturn by adivibos
Activities
Undertakw¥
Directly
Grnnt
Activitios
Support
Costs
2025
Total
Research 8nd raisNw awareness
I6,￿3
10.412
170,047
196,962
Ralslng
Awargness
76,503
2025
Total
16.503
16,503
Analysis olDlrgCt costs
Newsl8tler costs
Ralslng
2025
Total
99,386
1,453
13. 774
329
(223)
786
9.270
837
4. 131
624
3, 710
5,445
1,925
11,885
3, 186
4,270
187
2,826
2,803
2, 109
1,340
An•tysls of support costs
Staff costs
Staff lrnining 8nd ¢onlerwKes
Depre¢￿tion
Recniitment
Waler ral8S
Repai
Staff t7gency costs
Miscellaneous
Lic8ns&s 8nd subscnplions
Renl and seryice charge
Telephone and compuler
Print andp)st8ge
Insur8nc8
Equipment hire
Tr8vel
Legal atKI ptDfessional
88nk charges
Independent ex8minlA)n
OffKe costs
Cleaning and waste thsposal
Govemance cosls- Irustw Iravd rginbursed
99,386
1,453
13. T74
329
(223)
T86
9.270
837
4,131
624
3,710
5,445
1,925
11,885
3, 186
4,270
187
2.826
2,803
2.109
1,340
170,047
Grants to Grants to
Institutions Indlvldu8ls
70.412
2025
Total
10,472
Analysls ol Grants
Grants aw8rded
Page 21

INFLAMMATORY NEUROPATHIES UK
Notes lo the Financial Statements (continued)
for the year ended 31st March 2026
16. Fund eomparatlves (contlnued)
Funds
2025
AtIApr
2024
Incomlng
Outgolng
Resources Resources Transfers
At31 Mar
2025
Unrnstrlcted funds
Deswnaled funds
Propety lund
General fund
257,838
(5,567)
5,567
252,271
736.957
201.018
(203.228)
740,308
Total Unr6strl¢ted Funds
994. 789
201,018
203,228
992,579
The lunds are constiluled as lollows..
Des￿n&t&d funds...
Propety fund- this fund refl8cls the net book value of lh8 prop8ty held by GAIN.
2025
Total
UnTrstrlct8d
Funds
Tangible r￿ed assets
Fixed asset invgstmenl$
Current assets
c￿dI10
283.520
176,579
602,422
(9,942)
283,520
176,579
602,422
(9,942)
992 579
992 579
Page 22